Established amyloid-pathology is unaffected by chronic treatment with the selective serotonin reuptake inhibitor paroxetine

Severino, Maurizio; Sivasaravanaparan, Mithula; Olesen, Louise Ørum; von Linstow, Christian Ulrich; Metaxas, Athanasios; Bouzinova, Elena; Khan, Asif Manzoor; Lambertsen, Kate Lykke; Babcock, Alicia; Gramsbergen, Jan Bert; Wiborg, Ove; Finsen, Bente

Published in:
Alzheimer's & Dementia: Translational Research & Clinical Interventions

DOI:
10.1016/j.trci.2018.04.005

Publication date:
2018

Document version
Publisher's PDF, also known as Version of record

Document license
CC BY-NC-ND

Citation for published version (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal?

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Download date: 17. dec., 2018
Established amyloid-β pathology is unaffected by chronic treatment with the selective serotonin reuptake inhibitor paroxetine

Maurizio Severino, Mithula Sivasaravanaparan, Louise Ø. Olesen, Christian U. von Linstow, Athanasios Metaxas, Elena V. Bouzinova, Asif Manzoor Khan, Kate L. Lambersen, Alicia A. Babcock, Jan Bert Gramsbergen, Ove Wiborg, Bente Finsen

Department of Neurobiology, Institute of Molecular Medicine, University of Southern Denmark, Odense, Denmark
Center of Psychiatric Research, Aarhus University Hospital, Risskov, Denmark
Department of Neurology, Odense University Hospital, Odense, Denmark
BRIDGE – Brain Research -Inter-Disciplinary Guided Excellence, Department of Clinical Research, University of Southern Denmark, Odense, Denmark
Department of Health Science and Technology, Aalborg University, Aalborg, Denmark

Abstract

Introduction: Treatment with selective serotonin reuptake inhibitors has been suggested to mitigate amyloid-β (Aβ) pathology in Alzheimer’s disease, in addition to an antidepressant mechanism of action. Methods: We investigated whether chronic treatment with paroxetine, a selective serotonin reuptake inhibitor, mitigates Aβ pathology in plaque-bearing double-transgenic amyloid precursor protein (APP)sw/PS1DE9 mutants. In addition, we addressed whether serotonin depletion affects Aβ pathology. Treatments were assessed by measurement of serotonin transporter occupancy and high-performance liquid chromatography. The effect of paroxetine on Aβ pathology was evaluated by stereological plaque load estimation and Aβ42/Aβ40 ratio by enzyme-linked immunosorbent assay. Results: Contrary to our hypothesis, paroxetine therapy did not mitigate Aβ pathology, and depletion of brain serotonin did not exacerbate Aβ pathology. However, chronic paroxetine therapy increased mortality in APPsw/PS1DE9 transgenic mice. Discussion: Our results question the ability of selective serotonin reuptake inhibitor therapy to ameliorate established Aβ pathology. The severe adverse effect of paroxetine may discourage its use for disease-modifying purposes in Alzheimer’s disease.

Keywords: Alzheimer’s disease; Cerebral amyloidosis; Neocortex; Monoamine; Serotonin; Selective serotonin reuptake inhibitor; SERT occupancy; [3H]DASB; Autoradiography; Transgenic mouse model; 5,7-dihydroxytryptamine; Stereology

1. Introduction

The serotonergic system degenerates in Alzheimer’s disease (AD) along with the cholinergic and noradrenergic systems [1–3]. In patients with AD, the level of serotonin (5-hydroxytryptamine [5-HT]) is significantly reduced in several cortical regions, in particular in the frontal and temporal cortex [4,5]. This pathological change has been suggested to contribute to the depressive symptoms that frequently precede the cognitive decline in patients with AD [6–8]. It is still being disputed whether antidepressive treatment of patients with AD with selective serotonin reuptake inhibitors (SSRIs) impacts on the decline of cognition in AD [9–12] or the conversion from mild cognitive impairment to AD [13]. In AD, the density of specific cortical...
5-HT receptors correlates positively to amyloid β (Aβ) pathology and negatively to cognitive performance [14], with a reduced density of the 5-HT{sub}4R and 5-HT{sub}6R being observed in mild cognitive impairment [15–17]. Evidence that SSRI treatment impacts on Aβ accumulation comes from positron emission tomography studies, showing reduced uptake of Pittsburgh compound B, a proposed marker of Aβ pathology, in the brains of individuals with a history of SSRI therapy, including citalopram and fluoxetine [18]. In addition, acute, successive administration of citalopram (30 mg) to healthy individuals with 2 hours interval is reported to diminish cerebrospinal fluid levels of Aβ [19].

Interestingly, studies in transgenic mouse models of AD have suggested that SSRI treatment has major impact on Aβ pathology [18–20]. In the APP{sub}swe/PS1{sub}ΔE9 (amyloid precursor protein [APP]/presenilin 1 [PS1]) transgenic mouse, which is a well-established model of Aβ pathology [21], 4 months treatment with citalopram (8 mg/kg/day per os) from 3 months of age results in ∼50% lower Aβ plaque load in the neocortex at 7 months of age [18]. In 6-month-old APP/PS1 mice, 5 weeks of treatment with citalopram (10 mg/kg/day i.p.) impairs initial Aβ plaque formation and growth [18]. Five weeks treatment with paroxetine (5 mg/kg/day i.p.) from 5 months of age results in lower Aβ levels at 10 months of age in the hippocampus of 3 × Triple-Tg mice [20], a model of combined Aβ and tau pathology. In addition, 5-week treatment with fluoxetine (10 mg/kg/day i.p.) is suggested to reduce Aβ load in 18-month-old APP/PS1 mice [22], at an age when these mice show a reduction in 5-HT in the neocortex [23,24]. Finally, infusion of 5-HT into the hippocampus of APP/PS1 mice has been reported to reduce interstitial levels of Aβ [18], by mechanisms involving stimulation of the 5-HT{sub}4R and 5-HT{sub}6R and increased processing of APP via the nonamyloidogenic route [25,26].

Importantly, there are still no preclinical studies, where plaque-bearing APP/PS1 mice have been chronically treated with doses of SSRI, resulting in ≈80% occupancy of the serotonin transporter (SERT), which is considered therapeutic for the treatment of depression [27]. Therefore, we tested the hypothesis that chronic treatment of plaque-bearing 9-month-old APP/PS1 mice for 9 months with paroxetine (5 or 10 mg/kg/day per os) would mitigate Aβ pathology and improve behavior (locomotion, social memory). We also tested the hypothesis that a neurotoxin-induced loss of cortical 5-HT at 9 months of age would impact on Aβ pathology at 12 months. The results of this study question the proposed beneficial effect of SSRI therapy and 5-HT on Aβ pathology in mice with manifest Aβ pathology.

2. Methods

2.1. Paroxetine treatment and neurotoxin injection

Paroxetine: APP{sub}swe/PS1{sub}ΔE9 (APP/PS1) and littermate wild-type (Wt) mice [21] were bred on a B6C3 background in house or at Taconic A/S, Denmark [28]. Paroxetine (Se-roxat oral solution 2 mg/mL, GSKline) was administered in the drinking water in a dose of 10 mg/kg/day or 5 mg/kg/day (Table 1) to 9-month-old male APP/PS1 and Wt mice. APP/PS1 and Wt controls received normal drinking water. Treatment efficacy was assessed by autoradiographic measurement of the SERT occupancy using [3H]3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile, as detailed in Supplementary Methods.

Neurotoxin: To destroy 5-HT fibers and neurons, 5,7-dihydroxytryptophan (5,7-DHT) was stereotaxically injected into the lateral ventricles of 9-month-old male APP/PS1 and Wt mice (Table 1), as described elsewhere [31], but injecting a total dose of 80 μg 5,7-DHT. Mice with unsuccessful lesions, as determined by the measurement of 5-HT in neocortical tissues, were excluded from statistical analysis (Danish Veterinary & Food Administration: J.no. 2007/562-50, J.no. 2012-15-2935-00,023, J.no. 2012-DY-2934-00,008).

Tissue processing: See Supplementary Methods.

2.2. Behavior

The behavior of 18-month-old mice was assessed using the open field, the elevated plus maze, and the social

Table 1

<table>
<thead>
<tr>
<th>Experimental group</th>
<th>Treatment/intervention</th>
<th>Genotype</th>
<th>Treatment period (months)</th>
<th>Behavioral analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td>Wt (n)</td>
<td>APP/PS1 (n)</td>
<td></td>
</tr>
<tr>
<td>Nine months paroxetine treatment</td>
<td>Vehicle</td>
<td>20</td>
<td>14</td>
<td>9–18 months</td>
</tr>
<tr>
<td></td>
<td>Paroxetine 10 mg/kg/day</td>
<td>15</td>
<td>5</td>
<td>Open field, elevated plus maze, social interaction, social memory&lt;sup&gt;4&lt;/sup&gt; Y-maze&lt;sup&gt;5&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Vehicle</td>
<td>15</td>
<td>7</td>
<td>Open field, elevated plus maze, social interaction, social memory Y-maze&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td></td>
<td>Paroxetine 5 mg/kg/day</td>
<td>11</td>
<td>7</td>
<td>Not done</td>
</tr>
<tr>
<td>Three months paroxetine treatment</td>
<td>Vehicle</td>
<td>6</td>
<td>10</td>
<td>9–12 months</td>
</tr>
<tr>
<td></td>
<td>Paroxetine 10 mg/kg/day</td>
<td>6</td>
<td>7</td>
<td>Open field, social interaction, social memory Y-maze&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
<tr>
<td>Three months 5,7-DHT-induced loss of 5-HT</td>
<td>Sham</td>
<td>6</td>
<td>6</td>
<td>9–12 months</td>
</tr>
<tr>
<td></td>
<td>5,7-DHT</td>
<td>6</td>
<td>6</td>
<td>Open field, social interaction, social memory Y-maze&lt;sup&gt;1&lt;/sup&gt;</td>
</tr>
</tbody>
</table>

Abbreviations: 5,7-DHT, 5,7-dihydroxytryptophan; APP, amyloid precursor protein; 5-HT, 5-hydroxytryptamine; PS1, presenilin 1.

<sup>4</sup>Results reported in Olesen et al. [29].

<sup>5</sup>Results reported in Olesen et al. [30].

<sup>1</sup>Unpublished results.
interaction tests [29]. The 5,7-DHT-treated mice were assessed using the open field test [32]. All tests were performed in the light phase of 24-hr light/dark cycle. For details, see Supplementary Methods.

2.3. High-performance liquid chromatography for 5-HT

Monoamine levels were assessed in perchlorate extracts of the dissected tissues using high-performance liquid chromatography with electrochemical detection [24,32]. The detection limit for 5-HT was 30 fmol on column. The detection level in tissues was 0.25 pmol/mg wet weight.

2.4. Immunohistochemistry for human Aβ

Cryostat and vibratome sections were demasked free floating in 70% formic acid diluted in H2O for 15 min at room temperature, followed by staining for human Aβ using biotinylated monoclonal mouse-anti-Aβ immunoglobulin G1 (6E10, Biosite), which was detected by horse radish peroxidase-Streptavidin and developed with diaminobenzidine. Sections were mounted on glass-slides, dehydrated, and coverslipped from xylene in Depex. Paraffin sections were demasked in Tris-ethylenediaminetetraacetic acid-glucose-Buffer at 480 Watts for 15 min and stained as mentioned previously. The protocol for SERT is given in Supplementary Methods.

2.5. Enzyme-linked immunosorbent assay for human Aβ

Samples were processed according to the manufacturers protocol (Invitrogen), whereafter the Aβ was measured using Invitrogen Aβ42 Human enzyme-linked immunosorbent assay Kit (KHB3441) and Aβ40 Human enzyme-linked immunosorbent assay Kit (KHB3482), as described in Supplementary Materials. Data expressed in pg/mg protein were used for calculation of the Aβ42/Aβ40 ratio.

2.6. Quantification of Aβ plaque load

The Aβ plaque load was estimated in the neocortex by the use of stereological grid counting, using the new CAST software (Visiopharm), by an observer who was blinded to the treatment of the mice. The estimation was performed in 6.2 +/- 1.5 (mean +/- standard deviation) sections per mouse in the 18-month-old APP/PS1 mouse. For details, see Supplementary Methods. The percentage of neocortex covered by plaques in individual sections was calculated as: Aβ plaque load (%) = No. of Aβ+ plaques touching a cross (in a grid)/No. of crosses in neocortex X 100%. Plaque density was given by the number of plaques per area, and plaque size by the number of crosses hitting individual plaques. Data on Aβ plaque load are presented in dot diagrams, and plaque density and plaque size in bar graphs. The coefficient of error (CE) of the estimate of individual mice was used to calculate a mean CE for the group. The CE values and the coefficient of variation were calculated as done previously [33].

2.7. Statistical methods

Data sets were tested for normality of distribution. Bartlett’s test was used to check the equality of variances. Binary logistic regression was used to assess the effects of genotype, age, and treatment on mouse survival. Statistically significant differences between groups were evaluated using unpaired, two-tailed Student t tests, one-way analysis of variance (ANOVA), or repeated measures two-way ANOVA, followed by least significant difference post hoc tests. Analyses were performed using GraphPad software (Prism 4.0b) for Macintosh or XLSTAT (version 2010.3.06) for Windows. In one data set, one outlier >2 SDs from the mean was excluded. Statistical difference is indicated as *P < .05, **P < .01, ***P < .001, and ****P < .0001.

3. Results

3.1. 5-HT is reduced in aging APP/PS1 mice

The 18-month-old male APP/PS1 mice showed a reduction in 5-HT levels of ≈40% in frontal cortex compared with littermate Wt mice (P < .01, Student t test) (Fig. 1). This reduction is within the range previously reported for this AD model [23] and in line with the reduction in 5-HT levels observed in frontal cortex of AD patients [5,6].

3.2. Chronic paroxetine treatment reduces the survival of APP/PS1 mice

Individually caged 9-month-old male APP/PS1 and Wt mice were treated per os with paroxetine (Seroxat oral solution 2 mg/mL, GSKline) for up to 9 months, whereas vehicle-

![Fig. 1. 5-HT levels (pmol/mg wet weight) are reduced in frontal cortex of old APP/PS1 mice. HPLC measurement of 5-HT in the frontal cortex of 18-month-old male APP/PS1 Tg and Wt mice. Data are expressed as mean ± SEM. Student t test; Tg, n = 6; Wt, n = 5. **P < .01. Abbreviations: 5-HT, 5-hydroxytryptamine; APP, amyloid precursor protein; HPLC, high-performance liquid chromatography; SEM, standard error of the mean; PS1, presenilin 1; ww, wet weight of dissected brain tissue.](image-url)
treated mice received normal drinking water (Table 1). Paroxetine treatment at 10 mg/kg/day per os reduced the survival of APP/PS1 mice (Fig. 2). Binary logistic regression showed that the effect of treatment, genotype, and age on premature death was statistically significant ($\chi^2[3] = 166.2, P < .001$). The model explained 27.8% of the variance in premature deaths (Nagelkerke $R^2$), and correctly classified 88.3% of cases. The independent factors treatment (Wald score $= 39.3; P < .001$), genotype (Wald score $= 46.6; P < .001$), and age (Wald score $= 41.2; P < .001$) added significantly to the model and increased the likelihood of death by 4.8, 5.6, and 1.3, respectively. Because of the reduced survival rate, the dose of paroxetine was reduced to 5 mg/kg/day (Table 1), resulting in paroxetine serum levels of 40–50 nmol/L. Binary logistic regression of the effects of genotype, age, and 5 mg/kg/day paroxetine treatment was significant ($\chi^2[3] = 56.7, P < .001$), with the independent factors age (Wald score $= 41.2; P < .001$) and paroxetine (Wald score $= 5.3, P < .05$), but not genotype (Wald score $= 0.0; P > .05$), adding significantly to the model. Age and paroxetine treatment at 5 mg/kg/day per os increased the likelihood of premature death by 2.0 and 0.2, respectively.

3.3. Clinically relevant occupancy is achieved by oral paroxetine treatment

To ensure that all mice, including those treated with 5 mg/kg/day per os, were treated with a clinically relevant dose of paroxetine, we assessed the SERT occupancy in 18-month-old Wt mice treated with paroxetine in a dose of 5 mg/kg/day for 3 months. Vehicle-treated mice showed a high specific $[^3H]$-3-amino-4-(2-dimethylaminomethylphenylsulfanyl)-benzonitrile binding in all brain regions analyzed, except the cerebellum (data not shown). In neocortex, the occupancy of SERT in paroxetine-treated mice was 86% (Fig. 3). These results confirmed that the APP/PS1 and Wt mice were treated with paroxetine doses considered therapeutic in humans [27].

3.4. Long-term paroxetine treatment has no effect on established $\beta$-pathology

The effect of the 9-month oral SSRI treatment was examined by comparing the $\beta$-plaque load in 18-month-old paroxetine- and vehicle-treated APP/PS1 mice. The $\beta$-plaque load was estimated by the use of a stereological point counting technique. The plaque load in the neocortex showed to be comparable in paroxetine- and vehicle-treated mice (Student $t$ test: Veh, 18.0 ± 0.7% (mean ± standard error of the mean) vs. Prx, 16.5 ± 1.2%, $P = .27$) (Fig. 4A and 4B). The mean CE and coefficient of variation of the estimated plaque loads are shown in Table 2. In addition, no difference was noted in plaque density ($P = .66$, Student $t$ test), and plaque size ($P > .05$, all comparisons, Student $t$ test), between vehicle- and paroxetine-treated mice (Fig. 4C and 4D). The majority of the plaques (>99%) were smaller than 7.0 × 10$^3$ μm$^2$, a few ranged from 7.0–13.9 × 10$^3$ μm$^2$ (0.5%), and almost no plaques were larger than 14.0 × 10$^3$ μm$^2$ (Fig. 4D).
To evaluate if paroxetine treatment might reduce plaque load compared with baseline at the time when the paroxetine treatment was initiated, groups of 3- and 9-month-old male APP/PS1 mice were processed in parallel with the 18-month-old APP/PS1 and Wt mice. As previously shown for female APP/PS1 mice [28], the plaque load in the male APP/PS1 mice increased steadily from 3 months (0.04 ± 0.04%) through 9 months (8.1 ± 0.7%), to 18 months of age (19.8 ± 0.9%) [One-way ANOVA: F(2,28) = 110.1, P < .0001]. The plaque load in the paroxetine-treated 18-month-old APP/PS1 mice was thereby statistically higher than that in 9-month-old APP/PS1 mice (Student t test 16.5 ± 1.2% vs. 8.1 ± 0.7%, P < .0001).

In conclusion, 9-month oral paroxetine treatment (10 and 5 mg/kg/day) does not mitigate Aβ pathology in the neocortex of 18-month-old male APP/PS1 mice.

### 3.5. Paroxetine treatment impacts mouse behavior in both APP/PS1 and Wt mice

Effects of paroxetine treatment (5 mg/kg/day) were evaluated using the open field test, the elevated plus maze test, and the social interaction test. Repeated measures two-way ANOVA showed no significant effect of genotype in the open field (F[1,33] = 0.76, P > .05), no genotype by treatment interaction (F[1,33] = 0.18, P > .05), and only a tendency toward an effect of the paroxetine treatment (F[1,33] = 3.22, P = .08). Still, there was a significant effect of the paroxetine treatment that reduced locomotion given by the number of horizontal entries in both Wt and APP/PS1 mice (data not shown) (F[5,165] = 2.86, P = .02). No significant differences were observed in any parameters in the elevated plus maze.

### Table 2

<table>
<thead>
<tr>
<th>Treatment</th>
<th>n</th>
<th>% Aβ plaque load</th>
<th>CE</th>
<th>CV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Vehicle</td>
<td>18</td>
<td>18.0 ± 0.7</td>
<td>0.07</td>
<td>0.17</td>
</tr>
<tr>
<td>Paroxetine</td>
<td>12</td>
<td>16.5 ± 1.2</td>
<td>0.06</td>
<td>0.24</td>
</tr>
</tbody>
</table>

Abbreviations: SEM, standard error of the mean; Aβ, amyloid-β; CE, coefficient of error; CV, coefficient of variation; APP, amyloid precursor protein; PS1, presenilin 1.

NOTE. The CE and CV are calculated as in West et al. [29].

Fig. 4. No effect on Aβ pathology in 18-month-old APP/PS1 mice treated with paroxetine for 9 months. (A) Immunohistochemistry of coronal section for the human Aβ using the 6E10 antibody suggesting that the distribution and density of plaques is comparable in the neocortex of 18-month-old APP/PS1 mice treated with vehicle or paroxetine for 9 months. Bar: 200 µm. (B) Dot-diagram showing the % Aβ plaque load in APP/PS1 mice treated with vehicle or paroxetine for 9 months. The horizontal line indicates the mean and the error bars, the SEM. Statistical comparison shows no difference in % Aβ plaque load between groups (Student t test, P = .27). (C) Bar diagram showing the density of plaques in APP/PS1 treated with paroxetine (n = 12) or vehicle (n = 18). Student t test; P = .66. (D) Dot-diagram showing the size distribution in % of plaques counted in APP/PS1 mice treated with paroxetine (n = 12) or vehicle (n = 18). Student t test; P < .05, all comparisons. Abbreviations: Aβ, amyloid-β; APP, amyloid precursor protein; NCx, neocortex; SEM, standard error of the mean; Str, Striatum; Veh, vehicle; Prx, paroxetine; PS1, presenilin 1.
3.6. Short-term paroxetine treatment has no effect on Aβ pathology

In contrast to the studies by Cirrito et al. [18] and Nelson et al. [20] in which mice were treated with SSRI for 4 to 5 months and brains were processed for Aβ pathology at a younger age, we treated mice with paroxetine (10 mg/kg/day per os) or vehicle for 3 months and analyzed Aβ pathology in 12-month-old male APP/PS1 mice (Table 1) by quantifying plaque load in the right neocortex (Fig. 5A and 5B). There was no difference in plaque load between the paroxetine- and vehicle-treated APP/PS1 mice (P = .30, Student t test) (Fig. 5A). In addition, levels of Aβ42 and Aβ40 were unaffected by the treatment (P > .05, Student t test) (data not shown) as was the ratio of Aβ42/Aβ40 (P > .05, Student t test) (Fig. 5B), a risk parameter for AD [34].

3.7. Chronic loss of 5-HT has no effect on Aβ pathology or mouse behavior

We finally examined whether 5,7-DHT-induced serotonergic deafferentation of the forebrain of 9-month-old male APP/PS1 mice might impact Aβ pathology at 12 months of age (Table 1). The serotonergic deafferentation was validated by demonstration of undetectable levels of 5-HT and loss of SERT-immunopositive fibers in the neocortex (data not shown). The plaque load was comparable in sham-injected and deafferented APP/PS1 mice (2.4 ± 0.9% vs. 2.7 ± 0.6%, P = .29, Student t test) (Fig. 5C). Similarly, the levels of soluble Aβ42 and Aβ40 in the neocortex from the same mice were unaffected by the treatment (data not shown, P > .05, Student t test), as was the ratio of Aβ42/Aβ40 (P > .05, Student t test) (Fig. 5D). The behavioral testing at baseline in the open field test showed higher locomotor activity of APP/PS1 compared...
with Wt mice (P < .01, Student t test. APP/PS1: n = 22; Wt: n = 16). However, no significant differences were observed in the open field and social interaction tests between sham-injected and deafferented APP/PS1 mice at 12 months (data not shown, Sham: n = 6; 5,7-DHT: n = 6). These results suggest that 3-month impairment of 5-HT signaling has no effect on neither Aβ pathology nor behavior of 12-month-old APP/PS1 mice.

4. Discussion

4.1. Main findings

The main results of this study showed that chronic per os treatment with paroxetine of plaque-bearing 9-month-old APP/PS1 mice for up till 9 months was unable to mitigate Aβ pathology. However, treatment with paroxetine increased mortality for transgenic mice exclusively and reduced locomotion in both transgenic and littermate control mice. In addition, neurotoxin-induced serotonergic deafferentation of 9-month-old APP/PS1 mice had no impact on Aβ pathology in 12-month-old male APP/PS1 mice. These results were unexpected as previous studies have suggested that SSRIs mitigate Aβ pathology [18–20,22]. Considering the therapeutic implications of the potential option to impact directly on Aβ pathology in individuals developing AD, it is important to understand the background for these apparently contradictory results.

4.2. What is already known

Previous studies have reported reduced Aβ pathology after shorter periods of SSRI treatment in younger APP/PS1 and 3 × TgAD mice [18–20]. In Cirrito et al. [18], citalopram treatment of APP/PS1 mice from 3 to 7 months of age, resulted in a lower plaque load in neocortex of APP/PS1 mice. In the study by Sheline et al. [19], 4 weeks of citalopram treatment of 6-month-old APP/PS1 mice impaired the formation and growth of cortical plaques at 7 months [18]. Another study using 17-month-old APP/PS1 mice suggested that 5-week treatment with fluoxetine (10 mg/kg/day i.p.) was sufficient to mitigate plaque load; however, as acknowledged by the authors, the plaque load was not quantified [22]. In contrast, a study from our own group showed no or minor effect on the Aβ levels in neocortex and hippocampus in APP/PS1 mice treated from 3 to 9 months of age with escitalopram in a dose of 5 mg/kg/day per os, leading to ≈80% occupancy of SERT [31]. This suggests that the differences in results cannot simply be explained by differences in the time of treatment start, but that other factors, such as sex, genetic background, and type of SSRI should be taken into consideration. Studies suggest that the R-enantiomer present in citalopram but not in escitalopram may reduce levels of Aβ by SERT-independent mechanisms, possibly by increasing the γ-secretase activity, increasing the nonamyloidogenic processing of APP, and reducing the production of Aβ [35,36].

4.3. Strengths and limitations

The fact that the APP/PS1 and Wt mice were all littermates, of the same sex, and housed identically during their entire life span affords credibility to our findings of (1) a lack of effect of chronic paroxetine treatment on established Aβ pathology and (2) premature death by paroxetine treatment in APP/PS1 mice. APP/PS1 mice are known to exhibit seizure activity [37,38], which also occurs frequently in patients with AD [39]. Recently, fluoxetine administered in a dose of 15 mg/kg/day i.p. for 55 days to 19-week-old male APP/PS1 mice was found to increase seizure activity and mortality [40]. Although, the lowest paroxetine dose used in our study was 5 mg/kg/day, which is higher than the 0.3 mg/kg/day considered therapeutic in humans [27], it would be important to know if paroxetine in a dose of 0.3 mg/kg/day and therapeutic concentrations of e.g. citalopram increase seizure activity and mortality of AD transgenic mice. Importantly, we did not observe any mortality in the APP/PS1 mice treated with escitalopram (5 mg/kg/day per os) from 3 to 9 months of age [31]. It is also possible that chronic SSRI treatment, especially when administered i.p., may enhance stress and reduce survival in APP/PS1 mice. Under stressful conditions, SSRI treatment exaggerates, rather than ameliorates depressive-like symptoms in C57BL/6 mice [41]. In the present study, APP/PS1 and littermate Wt mice were treated with a clinically relevant paroxetine dose starting at an age when Aβ pathology is well established, but still increasing [28], similar to the progression of Aβ pathology in patients with AD [42]. Despite these similarities, the present results have been obtained in a mouse model and cannot be directly extrapolated to AD, which is a complex, polygenic neurodegenerative disease. Finally, it is increasingly recognized that Aβ pathology and associated molecular pathways represent only one out of several pathogenic mechanisms in AD, including tau pathology [43,44], brain inflammation [45], and cholinergic deficits [46], that can be modulated by serotonergic signaling in AD [47,48].

4.4. What does this study add and how to move forward?

In contrast to previous short-term studies using the same mouse model, this extended study demonstrated that chronic, long-term treatment with paroxetine did not ameliorate already established Aβ pathology in old APP/PS1 transgenic mice and selectively increased mortality in the APP/PS1 transgenic mice, but not in controls. Future studies, examining the effect of chronic treatment with newer generation SSRIs in APP/PS1 and tau transgenic mice, should be performed to determine whether the observed lack of beneficial effects and the serious adverse effect is specific for paroxetine. Knowing the answer to these questions is important for adjusting or reconsidering the wide-spread use of SSRIs in individuals with mild cognitive impairment and AD.
Acknowledgments

The authors thank Sussanne Petersen, Lene Jørgensen, and Inge Nielsen for their excellent technical assistance. The project was funded by the Lundbeck Foundation (A.A.B., B.F., and O.W.); the Danish Alzheimer’s Society (B.F. and O.W.); the Foundation Fonden til Lægevidenskabens Fremme (M.Se.), the Velux Foundation (B.F.), the University of Southern Denmark (SDU2020 B.F.), and the Danish Medical Research Council (A.A.B., B.F., O.W.).

Authors’ contribution: M.Se., M.Si., L.Ø.O., A.M., J.B.G., O.W., and B.F. designed the experiments, were responsible for carrying out the experiments, data analysis, and wrote the manuscript. For the behavioral experiments E.B. and K.L.L. helped with design and data analysis. A.M.K. assisted with surgery, and C.U.L. with histology in the same experiment. A.A.B. contributed to carrying out the experiments, and A.M. performed the SERT occupancy studies with the manuscript. Authors’ contribution: M.Se., M.Si., L.Ø.O., A.M., J.B.G., O.W., and B.F. designed the experiments, were responsible for carrying out the experiments, data analysis, and wrote the manuscript. For the behavioral experiments E.B. and K.L.L. helped with design and data analysis. A.M.K. assisted with surgery, and C.U.L. with histology in the same experiment. A.A.B. contributed to carrying out the experiments, and A.M. performed the SERT occupancy studies with the manuscript. All authors approved the manuscript.

Supplementary data

Supplementary data related to this article can be found at https://doi.org/10.1016/j.trci.2018.04.005.

References


